Complement C4 gene copy number variations and polymorphisms, autoantibodies, and clinical manifestations of juvenile dermatomyositis– a multi-center study

Abstract Juvenile dermatomyositis (JDM) is an autoimmune myopathy characterized by rash and muscle weakness. Complement C4 gene copy number (GCN) variation is a known risk factor for JDM. JDM patients often develop autoantibodies. We investigated the relationship between C4 GCN, clinical features, a...

Full description

Saved in:
Bibliographic Details
Published inJOURNAL OF IMMUNOLOGY Vol. 210; no. 1_Supplement; pp. 247 - 247.08
Main Authors Coss, Samantha Lynn, Aziz, Rabheh Abdul, Zhou, Danlei, Zhou, Bi, Miller, Katherine, Wu, Yee Ling, Ardoin, Stacy, Oberle, Edward, Driest, Kyla, Al Ahmed, Ohoud, Patwardhan, Anjali, Akoghlanian, Shoghik, Sivaraman, Vidya, Barbar-Smiley, Fatima, Drew, Joanne, Spencer, Charles, Pachman, Lauren, Morgan, Gabrielle, Mamyrova, Gulnara, Curiel, Rodolfo, Jones, Olcay, O’Hanlon, Terry, Rider, Lisa, Miller, Frederick, Padyukov, Leonid, Lundberg, Ingrid, Notarnicola, Antonella, Vencovský, Jiří, Stibůrková, Blanka, Kryštůfková, Olga, Yu, Chack-Yung
Format Journal Article Conference Proceeding
LanguageEnglish
Published 01.05.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Juvenile dermatomyositis (JDM) is an autoimmune myopathy characterized by rash and muscle weakness. Complement C4 gene copy number (GCN) variation is a known risk factor for JDM. JDM patients often develop autoantibodies. We investigated the relationship between C4 GCN, clinical features, and antibody development. METHODS: Subjects were recruited (n=255) from the US, Sweden, and the Czech Republic. C4 GCN was determined by real time PCR. Comparative analyses were performed via student’s t test or Mann Whitney U test. Correlation was assessed via linear regression or Fisher’s exact test. All studies were IRB approved, and informed consent was obtained. RESULTS: C4 GCN correlated with muscle pathology and extra-muscular disease at diagnosis. Lower C4A and C4L GCN were associated with a higher number of abnormal muscle enzymes (p=0.0062 and p=0.0029), while the opposite was true for C4S (p=0.024). Higher C4S GCN correlated with lower muscle strength scores (p=0.039). Lower C4L correlated with abnormal MRI (p= 0.042). C4B GCN correlated with dysphagia (p=0.035). Higher GCN of C4S was a risk factor for arthritis (p=0.032), systemic symptoms (p=0.020), and dysphagia (p=0.0078). C4 GCN was associated with myositis-specific (MSA) and myositis-associated (MAA) antibodies. Patients with homozygous C4A deficiency were more likely to test positive for anti-NXP2 (OR 20.0, p=0.011), and C4A GCN was lower in anti-NXP2 positive subjects (p=0.030). A higher C4B GCN correlated with positive MAA (p=0.043). DISCUSSION: Here, we show that low C4A/C4L GCN and high C4B/C4S GCN correlate with worse muscle disease, extra-muscular pathology, and autoantibodies. Our data suggest that complement C4 may play a key role in the ongoing pathogenesis of JDM. Supported by grants from NIH (R21 AR070509) and the CureJM Foundation
ISSN:0022-1767
1550-6606
DOI:10.4049/jimmunol.210.Supp.247.08